Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations

NCT06760819 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT06760819
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06760819 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Recruiting
Start date
February 13, 2025
Completion date
October 26, 2029
Enrollment
111 (estimated)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, her2 mutation